iSpecimen Inc. (ISPC) Tops Q2 EPS by 9c

iSpecimen Inc. (NASDAQ: ISPC) reported Q2 EPS of ($0.19), $0.09 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.86 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on iSpecimen Inc. (ISPC) click here.

You May Also Be Interested In

• Canaccord Downgrades Mayne Pharma Group Ltd. (MYX:AU) (MAYNF) to Spec. Buy
• Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso
• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS